Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
Abstract: The invention relates to the use of (1?.2?,4?.5?.7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane salts for preparing a pharmaceutical composition for the prevention and treatment of diseases associated with inflammation.
Type:
Grant
Filed:
August 20, 2003
Date of Patent:
August 9, 2011
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Abstract: A process for producing a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and a container produced according to this process, is described, wherein a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process forms a pressure equalisation opening in the outer container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are achieved. To do this, the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.
Type:
Grant
Filed:
July 17, 2007
Date of Patent:
August 2, 2011
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Abstract: The invention relates to a method of treating immunologic diseases or pathological conditions involving an immunologic component using certain Lck inhibitors already known as kinase inhibitors for therapy in oncology, optionally in combination with one or more other drugs selected from NSAIDs, steroids, DMARDs, immunsuppressives, biologic response modifiers and antinfectives, pharmaceutical compositions comprising said Lck inhibitors together with said other drugs, and the use of the Lck inhibitors for the manufacture of a pharmaceutical composition for the treatment of immunologic diseases or pathological conditions involving an immunologic component.
Type:
Grant
Filed:
December 12, 2008
Date of Patent:
August 2, 2011
Assignee:
Boehringer Ingelheim Pharma GmbH & Co. KG
Inventors:
Gerald Juergen Roth, Armin Heckel, Rainer Walter, Frank Hilberg, Rudolf Hauptmann, Martin Fredrich Stefanic, Florian Colbatzky, Steffan Ernest
Abstract: The present invention relates to the CGRP antagonists of general formula wherein A, X, D, E, G, M, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.
Type:
Grant
Filed:
February 17, 2010
Date of Patent:
July 26, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Stephan Georg Mueller, Klaus Rudolf, Philipp Lustenberger, Dirk Stenkamp, Alexander Dreyer, Kirsten Arndt, Gerhard Schaenzle, Henri Doods, Marco Santagostino, Fabio Paleari
Abstract: The invention relates to a powder inhaler (1) with mouthpiece (2) for dispersing pharmaceutical medicament formulations, which comprises an auxiliary energy source in the form of a pressure medium system (3), having a device for supplying (6) a powder formulation (7), while on activation of the pressure medium system a gaseous pressure medium (8) released by the pressure medium system (3) forms an aerosol (9) with the powder formulation (7) such that the powder particles are present in the gaseous pressure medium (8) in dispersed form. This is achieved by means of a powder inhaler (1) comprising a multi-channel nozzle, the channels of which are inclined to one another at an angle such that the aerosol jets flowing through them meet one another downstream behind the nozzle (10).
Type:
Grant
Filed:
March 4, 2005
Date of Patent:
July 26, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Dieter Hochrainer, Stephen Terence Dunne, Georg Boeck, Joerg Schiewe
Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2, R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
Type:
Grant
Filed:
April 23, 2007
Date of Patent:
July 19, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Matthias Treu, Andreas Mantoulidis, Ulrike Tontsch-Grunt
Abstract: A cartridge for propellant-free administration of a liquid pharmaceutical composition by inhalation includes: an elongate displacing device including an upper end and a lower end, the lower end for at least partial insertion into a container; a cartridge chamber disposed at the lower end of the displacing device and operable store a pharmaceutical formulation, the cartridge chamber including at least one pierceably sealed opening; and a cannula guide extending from the upper end of the displacing device to the cartridge chamber, wherein insertion of a cannula through the guide pierces the sealed opening and releases the pharmaceutical formulation into a liquid solvent in the container to form the liquid pharmaceutical composition.
Type:
Grant
Filed:
June 7, 2007
Date of Patent:
July 19, 2011
Assignee:
Boehringer Ingelheim Pharma GmbH & Co., KG
Abstract: The present invention relates to biarylbisphosphines and intermediates thereof. Furthermore, the scope of the invention encompasses catalysts which can be prepared from the bisarylphosphines and their use in asymmetric syntheses.
Abstract: An assay for use in high-throughput screening of chemical libraries to determine whether compounds in such libraries will inhibit CD38 catalytic activity, and CD38 production of ADPR and cADPR.
Type:
Grant
Filed:
November 10, 2006
Date of Patent:
July 12, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Susan Lukas, Gregory Whitten Peet, Brian Werneburg
Abstract: The present invention relates to new beta-agonists of general formula (I) wherein the groups R1 to R7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and their use as pharmaceutical compositions.
Type:
Grant
Filed:
May 1, 2008
Date of Patent:
July 12, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Thomas Trieselmann, Bradford S. Hamilton
Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
June 28, 2011
Assignee:
Boehringer Ingelheim Vetmedica, Inc.
Inventors:
Michael Roof, Phillip Hayes, Marc Eichmeyer, Greg Nitzel, Merrill Schaeffer
Abstract: The invention relates to a new crystalline anhydrate of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
Abstract: Foil bags are used as a primary packaging for liquids, the bags permitting the liquid to be taken therefrom without the application of a considerable amount of force. A container is provided for a medicinal liquid, the container being gas-tight and liquid-tight so that it is storable over many months. The container includes a collapsible foil bag on which a flange, which is stable in respect of shape, is disposed. The flange is designed for fitting onto a discharge connection member. The container can be disposed in a casing which is stable in respect of shape. The medicinal liquid does not come into contact with air and is protected from the effect of light. The medicinal liquid may be dispensed from the foil bag in many partial quantities over a prolonged period of time, with a respective partial amount thereof being converted into an aerosol by means of an atomizer.
Type:
Grant
Filed:
January 12, 2004
Date of Patent:
June 21, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Bernhard Freund, Dieter Hochrainer, Heinrich Kladders, Bernd Zierenberg, Joachim Eicher, Johannes Geser, Martin Essing, Holger Reinecke
Abstract: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.
Type:
Grant
Filed:
August 26, 2009
Date of Patent:
June 21, 2011
Assignee:
Boeringer Ingelheim Vetmedica S.A. de C.V
Inventors:
Raul Campogarrido, Carlos Gonzalez-Hernandez, Vaithianathan Sivanandan, Maria Elena Vazquez
Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.
Abstract: The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula (XIII) and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.
Type:
Grant
Filed:
January 25, 2007
Date of Patent:
June 14, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Juergen Schroeder, Georg Dziewas, Thomas Fachinger, Burkhard Jaeger, Carsten Reichel, Svenja Renner
Abstract: The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection.
Type:
Grant
Filed:
November 3, 2008
Date of Patent:
June 7, 2011
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Rebekah J. Carson, Lee Fader, Stephen Kawai, Serge R. Landry, Youla S. Tsantrizos, Christian Brochu, Sebastien Morin, Mathieu Parisien, Bruno Simoneau
Abstract: Disclosed is a process for preparing a compound of formula (I) by protecting the secondary amide nitrogen atom in the compound of formula (III) to obtain (IV) wherein PGN is a suitable nitrogen protecting group, ring-closing the compound of formula (IV) by cyclizing it in the presence of a suitable catalyst in a suitable organic solvent to obtain (V), and then deprotecting the resulting compound of formula (V) to obtain (I), as outlined in the following scheme. The compounds of formula (I) are active agents for the treatment of hepatitis C viral (HCV) infections or are intermediates useful for the preparation of anti-HCV agents.
Abstract: The invention provides for a substantially purified polypeptide referred to herein as CD38JL that is a CD38 splice variant comprised of the polypeptide of SEQ ID NO: 1 or a fragment thereof. The invention also provides methods for treating preventing and diagnosing disorders associated with expression of CD38JL.
Type:
Grant
Filed:
February 10, 2005
Date of Patent:
May 31, 2011
Assignee:
Boehringer Ingelheim Pharmaceutical, Inc.
Inventors:
Jun Li, Xiang Li, Baerbel LoSacco, Zhenhao Qi